|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 3.52M
Non-Canadian Issuer
2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 1.36M
3: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 58K
Liquidation or Succession
4: EX-4.29 Instrument Defining the Rights of Security Holders HTML 230K
5: EX-4.37 Instrument Defining the Rights of Security Holders HTML 1.10M
6: EX-4.38 Instrument Defining the Rights of Security Holders HTML 321K
7: EX-4.39 Instrument Defining the Rights of Security Holders HTML 56K
8: EX-4.40 Instrument Defining the Rights of Security Holders HTML 336K
9: EX-4.41 Instrument Defining the Rights of Security Holders HTML 315K
10: EX-4.42 Instrument Defining the Rights of Security Holders HTML 140K
11: EX-4.43 Instrument Defining the Rights of Security Holders HTML 128K
12: EX-4.44 Instrument Defining the Rights of Security Holders HTML 121K
13: EX-4.45 Instrument Defining the Rights of Security Holders HTML 314K
14: EX-4.46 Instrument Defining the Rights of Security Holders HTML 92K
15: EX-4.47 Instrument Defining the Rights of Security Holders HTML 122K
16: EX-4.48 Instrument Defining the Rights of Security Holders HTML 60K
17: EX-8.1 Opinion of Counsel re: Tax Matters HTML 38K
21: EX-13.1 Annual or Quarterly Report to Security Holders HTML 41K
22: EX-13.2 Annual or Quarterly Report to Security Holders HTML 41K
24: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 62K
Awarded Compensation
18: EX-11.1 Statement re: the Computation of Earnings Per HTML 67K
Share
19: EX-12.1 Statement re: the Computation of Ratios HTML 44K
20: EX-12.2 Statement re: the Computation of Ratios HTML 44K
23: EX-15.1 Letter re: Unaudited Interim Financial Info HTML 38K
30: R1 Document and Entity Information HTML 115K
31: R2 Consolidated Balance Sheets HTML 147K
32: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
33: R4 Consolidated Statements of Operations and HTML 185K
Comprehensive Loss
34: R5 Consolidated Statements of Stockholders' Equity HTML 90K
35: R6 Consolidated Statements of Cash Flows HTML 188K
36: R7 Description of Business HTML 87K
37: R8 Summary of Significant Accounting Policies HTML 96K
38: R9 Investment in Equity Securities, at Fair Value and HTML 187K
Long-Term Investments
39: R10 Inventories HTML 41K
40: R11 Leases HTML 89K
41: R12 Property, Plant and Equipment HTML 61K
42: R13 Intangible Assets HTML 111K
43: R14 Accrued and Other Current Liabilities, and Other HTML 76K
Liabilities
44: R15 Short Term Borrowings HTML 43K
45: R16 Notes Payable HTML 45K
46: R17 Grants HTML 42K
47: R18 Redeemable Noncontrolling Interest and Long Term HTML 68K
Borrowing
48: R19 Shareholders' Equity HTML 66K
49: R20 Costs of Revenues HTML 40K
50: R21 Net Loss Per Share HTML 65K
51: R22 Employee Benefit Plan HTML 42K
52: R23 Share-Based Compensation HTML 182K
53: R24 Income Taxes HTML 159K
54: R25 Fair Value Measurements HTML 118K
55: R26 Related Party Transactions HTML 48K
56: R27 Commitments and Contingencies HTML 44K
57: R28 Restricted Net Assets HTML 41K
58: R29 Subsequent Events HTML 41K
59: R30 Condensed Financial Information of Registrant HTML 220K
60: R31 Summary of Significant Accounting Policies HTML 164K
(Policies)
61: R32 Summary of Significant Accounting Policies HTML 50K
(Tables)
62: R33 Investment in Equity Securities, at Fair Value and HTML 170K
Long-Term Investments (Tables)
63: R34 Leases (Tables) HTML 88K
64: R35 Property, Plant and Equipment (Tables) HTML 57K
65: R36 Intangible Assets (Tables) HTML 111K
66: R37 Accrued and Other Current Liabilities, and Other HTML 76K
Liabilities (Tables)
67: R38 Redeemable Noncontrolling Interest (Tables) HTML 61K
68: R39 Shareholders' Equity (Tables) HTML 53K
69: R40 Net Loss Per Share (Tables) HTML 64K
70: R41 Share-Based Compensation (Tables) HTML 180K
71: R42 Income Taxes (Tables) HTML 159K
72: R43 Fair Value Measurements (Tables) HTML 117K
73: R44 Condensed Financial Information of Registrant HTML 222K
(Tables)
74: R45 DESCRIPTION OF BUSINESS - Liquidity and Capital HTML 111K
Resources (Details)
75: R46 DESCRIPTION OF BUSINESS - License and Distribution HTML 51K
Agreements (China Resources Pharmaceutical
Commercial Group International Trading Co., Ltd.)
(Details)
76: R47 DESCRIPTION OF BUSINESS - License and Distribution HTML 50K
Agreements (Precision Autoimmune Therapeutics Co.,
Ltd) (Details)
77: R48 DESCRIPTION OF BUSINESS - License and Distribution HTML 47K
Agreements (Juventas Cell Therapy Ltd.) (Details)
78: R49 DESCRIPTION OF BUSINESS - License and Distribution HTML 72K
Agreements (BioInvent International AB) (Details)
79: R50 DESCRIPTION OF BUSINESS - License and Distribution HTML 54K
Agreements (Black Belt Therapeutics Limited)
(Details)
80: R51 DESCRIPTION OF BUSINESS - License and Distribution HTML 56K
Agreements (Cleave Therapeutics, Inc.) (Details)
81: R52 DESCRIPTION OF BUSINESS - License and Distribution HTML 48K
Agreements (Pharmathen Global BV) (Details)
82: R53 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 41K
Consolidation (Details)
83: R54 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 40K
Segment Reporting (Details)
84: R55 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash HTML 47K
and Cash Equivalents (Details)
85: R56 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 46K
Aggregate Cost And Fair Value (Details)
86: R57 Summary of Significant Accounting Policies - Ppe HTML 48K
(Details)
87: R58 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 66K
LONG-TERM INVESTMENTS - Investment in equity
securities, at fair value-MaxCyte Inc. (Details)
88: R59 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 94K
LONG-TERM INVESTMENTS - Investment in equity
securities, at fair value-BioInvent International
AB ordinary shares and warrants (Details)
89: R60 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 71K
LONG-TERM INVESTMENTS - BioInvent International AB
- Summary of Investments (Details)
90: R61 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 66K
LONG-TERM INVESTMENTS - Summary of Long-term
investments (Details)
91: R62 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 86K
LONG-TERM INVESTMENTS - Investment in equity
securities, at fair value-Juventas Cell Therapy
Ltd. (Details)
92: R63 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 89K
LONG-TERM INVESTMENTS - Investment in equity
securities, at fair value-Alesta Therapeutics B.V.
(Details)
93: R64 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 78K
LONG-TERM INVESTMENTS - Investment in equity
securities, at fair value-Cleave Therapeutics,
Inc. (Details)
94: R65 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 75K
LONG-TERM INVESTMENTS - Investment in Precision
Autoimmune Therapeutics Co Ltd (Pat) (Details)
95: R66 Inventories (Details) HTML 43K
96: R67 Leases - (Details) HTML 57K
97: R68 Leases - Right of Use Assets and Liabilities HTML 51K
(Details)
98: R69 LEASES - Supplemental Cash Flow (Details) HTML 45K
99: R70 LEASES - Future Undiscounted Cash Flows (Details) HTML 61K
100: R71 PROPERTY, PLANT AND EQUIPMENT - Narratives HTML 50K
(Details)
101: R72 PROPERTY, PLANT AND EQUIPMENT - By type (Details) HTML 55K
102: R73 INTANGIBLE ASSETS - Narratives (Details) HTML 72K
103: R74 INTANGIBLE ASSETS - Net Definite-lived Intangible HTML 59K
Assets (Details)
104: R75 INTANGIBLE ASSETS - Intangible Assets Rollforward HTML 50K
(Details)
105: R76 INTANGIBLE ASSETS - Expected Future Amortization HTML 52K
Expense (Details)
106: R77 Accrued and Other Current Liabilities, and Other HTML 73K
Liabilities (Details)
107: R78 Short Term Borrowings (Details) HTML 63K
108: R79 Notes Payable (Details) HTML 50K
109: R80 Grants (Details) HTML 51K
110: R81 Redeemable Noncontrolling Interest and Long Term HTML 96K
Borrowing (Details)
111: R82 Redeemable Noncontrolling Interest and Long Term HTML 51K
Borrowing - Changes in Redeemable Noncontrolling
Interest (Details)
112: R83 Shareholders' Equity (Details) HTML 83K
113: R84 Shareholders' Equity - Warrants Activity (Details) HTML 52K
114: R85 Costs of Revenues (Details) HTML 42K
115: R86 Net Loss Per Share (Details) HTML 43K
116: R87 Net Loss Per Share - Basic and diluted net loss HTML 70K
per share computation (Details)
117: R88 Employee Benefit Plan (Details) HTML 44K
118: R89 SHARE-BASED COMPENSATION - Compensation Expense HTML 55K
(Details)
119: R90 SHARE-BASED COMPENSATION - Weighted-Average HTML 55K
Assumptions (Details)
120: R91 SHARE-BASED COMPENSATION - Options Outstanding HTML 95K
(Details)
121: R92 SHARE-BASED COMPENSATION - Stock Option HTML 70K
Outstanding (Details)
122: R93 Share-Based Compensation (Details) HTML 86K
123: R94 INCOME TAXES - Loss Before Income Taxes (Details) HTML 50K
124: R95 INCOME TAXES - Deferred Income Tax Assets And HTML 72K
Liabilities (Details)
125: R96 INCOME TAXES - Reconciliation Of The Provision For HTML 65K
Income Taxes (Details)
126: R97 INCOME TAXES - Valuation allowance (Details) HTML 47K
127: R98 INCOME TAXES - Gross Unrecognized Tax Benefits HTML 45K
(Details)
128: R99 Income Taxes (Details) HTML 77K
129: R100 FAIR VALUE MEASUREMENTS - Financial and HTML 67K
Non-Financial Assets and Liabilities (Details)
130: R101 FAIR VALUE MEASUREMENTS - Quantitative Information HTML 50K
about Level 3 Fair Value Measurements (Details)
131: R102 Fair Value Measurements (Details) HTML 62K
132: R103 Related Party Transactions (Details) HTML 83K
133: R104 Commitments and Contingencies (Details) HTML 58K
134: R105 Restricted Net Assets (Details) HTML 40K
135: R106 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 150K
Condensed Balance Sheets (Details)
136: R107 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 108K
Condensed Statements of Operations and
Comprehensive Loss (Details)
137: R108 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 108K
Condensed Statements of Cash Flows (Details)
139: XML IDEA XML File -- Filing Summary XML 243K
142: XML XBRL Instance -- casi-20231231x20f_htm XML 3.57M
138: EXCEL IDEA Workbook of Financial Report Info XLSX 249K
26: EX-101.CAL XBRL Calculations -- casi-20231231_cal XML 267K
27: EX-101.DEF XBRL Definitions -- casi-20231231_def XML 1.32M
28: EX-101.LAB XBRL Labels -- casi-20231231_lab XML 1.83M
29: EX-101.PRE XBRL Presentations -- casi-20231231_pre XML 1.74M
25: EX-101.SCH XBRL Schema -- casi-20231231 XSD 324K
140: JSON XBRL Instance as JSON Data -- MetaLinks 668± 1.06M
141: ZIP XBRL Zipped Folder -- 0001558370-24-004190-xbrl Zip 1.32M
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (No. 333-222043-01, 333-228980-01, 333-188042-01 and 333-258819-01) on Form S-8 of our report dated March 28, 2024, with respect to the consolidated financial statements of CASI Pharmaceuticals, Inc.
/s/ KPMG Huazhen LLP
Beijing, China
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/28/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||